|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus显示文摘 | Alexander J. Thompson Andrew J. Muir Mark S. Sulkowski Dongliang Ge Jacques Fellay Kevin V. Shianna Thomas Urban Nezam H. Afdhal Ira M. Jacobson Rafael Esteban Fred Poordad Eric J. Lawitz Jonathan McCone Mitchell L. Shiffman Greg W. Galler William M. Lee | 2010 | Gastroenterology2010，，1： | 7 |
| 2 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 5 |
| 3 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial显示文摘 | Eric Lawitz Fred F Poordad Phillip S Pang Robert H Hyland Xiao Ding Hongmei Mo William T Symonds John G McHutchison Fernando E Membreno | 2013 | The Lancet2013，，： | 5 |
| 4 | Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents显示文摘 | F. Poordad D. Dieterich | 2012 | Journal of Viral Hepatitis2012，，7： | 4 |
| 5 | Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis显示文摘 | Savino Bruno John M. Vierling Rafael Esteban Lisa M. Nyberg Hugo Tanno Zachary Goodman Fred Poordad Bruce Bacon Keith Gottesdiener Lisa D. Pedicone Janice K. Albrecht Clifford A. Brass Seth Thompson Margaret H. Burroughs | 2012 | Journal of Hepatology2012，，： | 2 |
| 6 | Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy显示文摘 | Nezam H. Afdhal Geoffrey M. Dusheiko Edoardo G. Giannini Pei–Jer Chen Kwang–Hyub Han Aftab Mohsin Maribel Rodriguez–Torres Sorin Rugina Igor Bakulin Eric Lawitz Mitchell L. Shiffman Ghias–Un–Nabi Tayyab Fred Poordad Yasser Mostafa Kamel Andres Brainsky Ja | 2014 | Gastroenterology2014，，2： | 2 |
| 7 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir显示文摘 | Fred Poordad Jean–Pierre Bronowicki Stuart C. Gordon Stefan Zeuzem Ira M. Jacobson Mark S. Sulkowski Thierry Poynard Timothy R. Morgan Cliona Molony Lisa D. Pedicone Heather L. Sings Margaret H. Burroughs Vilma Sniukiene Navdeep Boparai Venkata S. Goteti | 2012 | Gastroenterology2012，，3： | 2 |
| 8 | Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy显示文摘 | Kevin D. Mullen Arun J. Sanyal Nathan M. Bass Fred F. Poordad Muhammad Y. Sheikh R. Todd Frederick Enoch Bortey William P. Forbes | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 2 |
| 9 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients显示文摘BACKGROUND The hepatitis C virus(HCV) NS5A inhibitor ABT-267(ombitasvir, OBV), the HCV NS4/4A protease inhibitor ABT-450(paritaprevir, PTV), the CYP3A inhibitor ritonavir(r) and the non-nucleoside NS5B polymerase inhibitor ABT-333(dasabuvir, DSV)(OBV/PTV/r + DSV) with or without ribavirin(RBV) is a direct-acting antiviral regimen approved in the United States and other major countries for the treatment of HCV in genotype 1(GT1) infected patients. Patients with HCV who are considered 'hard-to-cure' have generally been excluded from registration trials due to rigorous study inclusion criteria, presence of comorbidities and previous treatment failures.AIM To investigate the efficacy of this regimen in HCV G1-infected patients historically excluded from clinical trials.METHODS Patients were ≥ 18 years old and chronically infected with HCV GT1(GT1a, GT1b or GT1a/1b). Patients were treatment-na?ve or previously failed a regimen including pegylated interferon/RBV +/-telaprevir, boceprevir, or simeprevir.One hundred patients were treated with the study drug regimen, which was administered for 12 or 24 wk +/-RBV according to GT1 subtype and presence/absence of cirrhosis. Patients were evaluated every 4 wk from treatment day 1 and at 4 and 12 wk after end-of-treatment.RESULTS Many of the patients studied had comorbidities(44.2% hypertensive, 33.7%obese, 20.2% cirrhotic) and 16% previously failed HCV treatment. Ninety-six patients completed study follow-up and 99% achieved 12-wk sustained virologic response. The majority(88.4%) of patients had undetectable HCV RNA by week 4. The most common adverse events were fatigue(12%), headache(10%),insomnia(9%) and diarrhea(8%); none led to treatment discontinuation. Physical and mental patient reported outcomes scores significantly improved after treatment. Almost all(98%) patients were treatment compliant.CONCLUSION In an all-comers HCV GT1 population, 12 or 24-wk of OBV/PTV/r + DSV +/-RBV is highly effective and tolerable and results in better mental and physical health following treatment. | Nicole Loo Eric Lawitz Naim Alkhouri Jennifer Wells Carmen Landaverde Angie Coste Rossalynn Salcido Michael Scott Fred Poordad | 2019 | World Journal of Gastroenterology2019，25，18： | 2 |
| 10 | Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response显示文摘 | John M. Vierling Mitchell Davis Steven Flamm Stuart C. Gordon Eric Lawitz Eric M. Yoshida Joseph Galati Velimir Luketic Jonathan McCone Ira Jacobson Patrick Marcellin Andrew J. Muir Fred Poordad Lisa D. Pedicone Janice Albrecht Clifford Brass Anita Y.M. H | 2013 | Journal of Hepatology2013，，： | 2 |
| 11 | 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NA?VE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL显示文摘 | M. Manns P. Marcellin F.P. Fred Poordad E. Stanislau Affonso de Araujo M. Buti Y. Horsmans E.J. Ewa Janczewska F. Villamil M. Peeters O. Lenz S. Ouwerkerk-Mahadevan R. Kalmeijer M. Beumont-Mauviel | 2013 | Journal of Hepatology2013，，： | 2 |
| 12 | 聚乙二醇干扰素/利巴韦林治疗丙型肝炎期间发生的感染与绝对淋巴细胞计数下降相关显示文摘虽然聚乙二醇干扰素(PEG-INF)治疗丙型肝炎期间常引起骨髓抑制,但白细胞计数的下降与发生感染风险的关系仍未确定。一项随机、平行、多中心Ⅲ期IDEAL(Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy)研究,旨在确定PEGINF/利巴韦林治疗丙型肝炎期间感染发生的概率和危险因素。 | Melia MT Brau N Poordad F 何高丽 张菁 | 2015 | 中国感染与化疗杂志2015，15，4： | 2 |
| 13 | Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis显示文摘 | Lawitz E Poordad F Brainard DM | 2015 | Hepatol2015，61，3： | 1 |
| 14 | Hepatic Encephalopathy显示文摘 | Vandana Khungar Fred Poordad | 2012 | Clinics in Liver Disease2012，，2： | 1 |
| 15 | Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents显示文摘 | F. Poordad D. Dieterich | 2012 | Journal of Viral Hepatitis2012，，7： | 1 |
| 16 | Retreatment with telaprevir combination therapy in hepatitis C patients with well- characterized prior treatment response显示文摘 | Muir AJ Poordad FF McHutchison JG | 2011 | Hepatology2011，54，5： | 1 |
| 17 | Management of overt hepatic encephalopathy显示文摘 | Khungar V Poordad F | | 0，，1： | 1 |
| 18 | 1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT显示文摘 | S. Zeuzem G.R. Foster M.W. Fried C. Hezode G.M. Hirschfleld I. Nikitin F. Poordad O. Lenz M. Peeters V. Sekar G. De Smedt | 2011 | Journal of Hepatology2011，，： | 1 |
| 19 | Hepatitis C infection and the patient with end-stage renal disease显示文摘 | Fabrizi F Poordad FF Martin P | 2002 | Hepatology2002，36，1： | 1 |
| 20 | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype I infection with compensated cirrhosis显示文摘 | Muir AJ Poordad F LaIezari J | 2015 | JAMA2015，313，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员